TechnoVax Inc. Receives $2.9 Million Grant for Flu and Influenza Virus-Like Particle (VLP) Vaccine Program

TARRYTOWN, N.Y.--(BUSINESS WIRE)--TechnoVax, Inc., a biotechnology developer of novel vaccines was awarded a three-year $2.9 million SBIR phase II grant from the National Institutes of Health to further the development of its VLP-based, vaccine program.

Back to news